Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 2/2012

01-02-2012 | Research Articles

Ten-year results of a phase II study with a single fraction of high-dose-rate brachytherapy (FAST-boost) after whole breast irradiation in invasive breast carcinoma

Authors: José Luis Guinot, M. Isabel Tortajada, María Carrascosa, Vicente Crispín, Ana Otero, Belén Ríos, Eleonor Rivin, Miguel Santos, Pablo Soler, Leoncio Arribas

Published in: Clinical and Translational Oncology | Issue 2/2012

Login to get access
Metadata
Title
Ten-year results of a phase II study with a single fraction of high-dose-rate brachytherapy (FAST-boost) after whole breast irradiation in invasive breast carcinoma
Authors
José Luis Guinot
M. Isabel Tortajada
María Carrascosa
Vicente Crispín
Ana Otero
Belén Ríos
Eleonor Rivin
Miguel Santos
Pablo Soler
Leoncio Arribas
Publication date
01-02-2012
Publisher
Springer Milan
Published in
Clinical and Translational Oncology / Issue 2/2012
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-012-0769-3

Other articles of this Issue 2/2012

Clinical and Translational Oncology 2/2012 Go to the issue

Educational Series / Blue Series

Nanoparticle delivery systems for cancer therapy: advances in clinical and preclinical research

Research Articles

Circulating tumour cells in prostate cancer patients receiving salvage radiotherapy

Review

Review of Chinese clinical trials on CIK cell treatment for malignancies

Editorial

Neoadjuvant endocrine therapy: for whom, for how long?

Research Articles

Examination of Smad2 and Smad4 copy-number variations in skin cancers

Research Articles

Phase II trial with letrozole to maximum response as primary systemic therapy in postmenopausal patients with ER/PgR[+] operable breast cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits